trifluridine has been researched along with Colorectal Cancer in 232 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (2.16) | 29.6817 |
| 2010's | 98 (42.24) | 24.3611 |
| 2020's | 129 (55.60) | 2.80 |
| Authors | Studies |
|---|---|
| Ananda, S; Banks, S; Dunn, C; Gard, G; Gately, L; Gibbs, P; Jalali, A; Jennens, R; Khattak, A; Kosmider, S; Lee, B; Lee, M; Lim, L; Loft, M; McKendrick, J; Shapiro, JD; Tie, J; Wong, HL; Wong, R; Yeung, JM | 1 |
| Abdel-Raouf, S; Angelis, V; Barry, A; Baxter, M; Chauhan, M; Eccles, B; Graham, JS; Hill, M; Holden, C; Iveson, T; Karampera, C; Khan, S; Martinou, M; Mills-Baldock, T; Pouptsis, A; Ross, PJ; Satterthwaite, L; Shiu, KK; Stavraka, C; Synowiec, A; Thomas, A; Young, S | 1 |
| En, W; Fukuoka, T; Hirakawa, K; Iseki, Y; Kashiwagi, S; Ohira, M; Okazaki, Y; Shibutani, M | 1 |
| Kaddah, MMY; Keshk, RM; Talaat, W | 1 |
| Giuliani, J | 1 |
| Alsina, M; Benhadji, KA; Cicin, I; Doi, T; Hosaka, H; Ilson, DH; Longo, F; Makris, L; Özgüroğlu, M; Ozyilkan, O; Park, D; Pericay, C; Santoro, A; Shitara, K; Thuss-Patience, P; Zaanan, A | 1 |
| Ettrich, TJ; Heinemann, V; Hess, J; Karthaus, M; Klein, A; Kretzschmar, A; Pelz, H; Reisländer, T; Riera-Knorrenschild, J; Vehling-Kaiser, U; Weiss, L; Welslau, M | 1 |
| Basto, R; Bonito, N; Gomes, I; Jacinto, P; Magalhães, J; Paulo, J; Pereira, TC; Sousa, G; Sousa, MJ | 1 |
| Antista, M; Antoniotti, C; Boccaccino, A; Borelli, B; Bosco, MF; Carullo, M; Conca, V; Cosentino, P; Cremolini, C; Germani, MM; Giordano, M; Marmorino, F; Martini, S; Masi, G; Moretto, R; Pietrantonio, F; Prisciandaro, M; Rossini, D; Vetere, G; Zaffaroni, N; Zucchelli, G; Zuco, V | 1 |
| Artru, P; Bouché, O; Coriat, R; Coutzac, C; De La Fouchardière, C; Doat, S; Gallois, C; Henriques, J; Masson, T; Moulin, V; Saint, A; Taieb, J; Tougeron, D; Trouilloud, I; Vernerey, D | 1 |
| Dijksterhuis, WPM; Elferink, MAG; Hamers, PAH; Koopman, M; May, AM; Punt, CJA; Stellato, RK; Vink, GR | 1 |
| Boku, N; Hirano, H; Iwasa, S; Okita, N; Oshima, K; Shoji, H; Takashima, A | 1 |
| Amellal, N; Aubel, P; Cattan, V; Fougeray, R; Kim, TW; Li, J; Mayer, RJ; Ohtsu, A; Shen, L; Sriuranpong, V; Van Cutsem, E; Xuereb, L; Yoshino, T | 1 |
| Chuang, J; Fakih, M; Gong, J; Li, SM; Wang, C | 1 |
| Bonetti, A; Giuliani, J; Mantoan, B | 1 |
| Andersson, CR; Fasterius, E; Fryknäs, M; Jarvius, M; Larsson, R; Selvin, T | 1 |
| Dechow, T; Ettrich, TJ; Fruehauf, S; Fuchs, M; Heinemann, V; Hoyer, I; Kaiser, F; Karthaus, M; Kiani, A; König, A; Kurreck, A; Modest, DP; Müller, L; Quante, M; Reinacher-Schick, A; Roderburg, C; Schwaner, I; Sommerhäuser, G; Stahler, A; Stintzing, S; von Weikersthal, LF | 1 |
| Astaras, C; Buccella, Y; De Dosso, S; Helbling, D; Lo Presti, G; Siebenhüner, AR; Szturz, P | 1 |
| Chucla, TC; De Castro, BA; de la Cámara Gomez, J; Diaz, SS; Fernández, FB; Lopez, MR; Martínez-Lago, N; Ponte, RV; Rendo, CR; Rodriguez, MIG; Salvador, MM; Suarez, BG | 1 |
| Babajanyan, S; Barzi, A; Bekaii-Saab, T; Cho, SK; Hocum, B; Kavati, A | 1 |
| Arrichiello, G; Ciardiello, D; Ciardiello, F; De Falco, V; Facchini, G; Famiglietti, V; Incoronato, P; Laterza, MM; Martinelli, E; Martini, G; Nacca, V; Napolitano, R; Napolitano, S; Nicastro, A; Paragliola, F; Perrone, A; Suarato, G; Troiani, T | 1 |
| Chen, YC; Dragovich, T; Jimeno, A; Kopetz, S; Kundranda, M; Lieu, C; Menter, D; Pant, S; Tchaparian, E | 1 |
| Arkenau, HT; Benhadji, KA; Doi, T; Falcone, A; George, B; Hochster, H; Ilson, DH; Makris, L; Mayer, R; Ohtsu, A; Shitara, K; Tabernero, J; Van Cutsem, E; Yoshino, T | 1 |
| Amellal, N; André, T; Aubel, P; Campos-Bragagnoli, A; Chmielowska, E; Csöszi, T; Falcone, A; Fougeray, R; Liposits, G; Martín, L; Moiseenko, F; Polo-Marques, E; Saunders, MP; Shparyk, Y | 1 |
| de Castro, NM; García-Beloso, N; Gayoso-Rey, M; López-López, A; Piñeiro-Corrales, G; Robles-Torres, D; Romero-Ventosa, EY | 1 |
| Atreya, CE; Carnevale, J; Cinar, P; Fidelman, N; Griffith, M; Milloy, MA; Van Loon, K; Venook, AP | 1 |
| Chen, B; Chen, X; He, Y; Liu, Y; Lv, H; Nie, C; Wang, J; Wang, S; Xu, W; Zhao, J | 1 |
| Antista, M; Antoniotti, C; Boccaccino, A; Borelli, B; Conca, V; Cremolini, C; Crucitta, S; Cucchiara, F; Danesi, R; Del Re, M; Germani, MM; Leone, AG; Marmorino, F; Masi, G; Moretto, R; Pietrantonio, F; Provenzano, L; Rossini, D; Spagnoletti, A | 1 |
| Fujioka, A; Hayashi, H; Nagase, H; Nukatsuka, M; Tanaka, G | 1 |
| Cheung, WY; Ding, PQ; Dolley, A | 1 |
| Bachet, JB; Chevallier, B; Price, T; Taieb, J; Vidot, L; Wyrwicz, L | 1 |
| Ikoma, T; Matsumoto, T; Miura, K; Nagai, H; Takatani, M; Tsuduki, T; Watanabe, T; Yamamura, S; Yasui, H | 1 |
| Florou, V; Garrido-Laguna, I; Haaland, B; Nevala-Plagemann, C; Sama, S; Shen, J; Ying, J | 1 |
| Hara, H; Ishihara, S; Kagawa, Y; Kajiwara, T; Kawakami, H; Kotaka, M; Kuboki, Y; Makiyama, A; Masuishi, T; Morita, S; Nakajima, TE; Nakamura, M; Ojima, H; Oki, E; Ozawa, D; Shirao, K; Sugimoto, N; Sunakawa, Y; Takashima, A; Takenaka, N; Taniguchi, H; Terazawa, T; Watanabe, J; Yoshino, T | 1 |
| Araujo, KB; Festa, J; Mardegan, L; Meton, F; Piranda, DN; Victorino, APOS | 1 |
| Fujii, H; Hirose, C; Iihara, H; Kiyama, S; Kobayashi, R; Makiyama, A; Matsuhashi, N; Matsuoka, S; Ohata, K; Sadaka, S; Suzuki, A; Takahashi, T; Watanabe, D | 1 |
| Benhadji, KA; Doi, T; Ghidini, M; Hochster, H; Makris, L; Mansoor, W; Takahashi, O; Van Cutsem, E | 1 |
| Amellal, N; Benhadji, KA; Bondarenko, I; Ciardiello, F; Cremolini, C; Cruz, FM; Elez, E; Fakih, M; Leger, C; Liposits, G; Modest, DP; Pápai, Z; Poureau, PG; Prager, GW; Stroyakovskiy, D; Tabernero, J; Taieb, J; Van Cutsem, E; Vidot, L; Wyrwicz, L | 1 |
| Altucci, L; Avallone, A; Bordonaro, R; Cardone, C; Ciardiello, D; Ciardiello, F; De Falco, V; De Stefano, A; De Vita, F; Della Corte, CM; Di Liello, A; Di Maio, M; Esposito, L; Famiglietti, V; Marrone, F; Martinelli, E; Martini, G; Montesarchio, V; Napolitano, S; Santini, D; Scartozzi, M; Troiani, T; Zampino, MG | 1 |
| Benhadji, KA; Fakih, MG; George, B; Ghidini, M; Makris, L; Shitara, K; Sundar, R; Taieb, J | 1 |
| Berres, ML; Gonzalez-Carmona, M; Kehmann, L; Keitel, V; Luedde, T; Modest, DP; Mohr, R; Roderburg, C; Strassburg, C; Trautwein, C; Venerito, M; Wree, A | 1 |
| Furusawa, K; Furuse, J; Furuta, M; Hamaguchi, T; Hashimoto, I; Hayashi, K; Inokuchi, Y; Kanematsu, K; Machida, N; Maeda, S; Nagasawa, S; Notsu, A; Ogata, T; Onuma, S; Oshima, T; Suematsu, H; Watanabe, M; Yamada, T | 1 |
| Bruch, HR; de Buhr, R; Decker, T; Frank, M; Göhler, T; Grundeis, M; Grunewald, R; Harich, HD; Hartmann, F; Hogrefe, C; Kojouharoff, G; Kröning, H; Liersch, R; Lipke, J; Marschner, N; Moorahrend, E; Nusch, A; Potthoff, K; Reisländer, T; Sauer, A; Schwaner, I; Semsek, D; Stephany, M; Uhlig, J; Vehling-Kaiser, U; Welslau, M | 1 |
| Ando, M; Hamauchi, S; Honda, K; Kadowaki, S; Kawakami, T; Masuishi, T; Mori, K; Muro, K; Narita, Y; Onozawa, Y; Shirasu, H; Taniguchi, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T | 1 |
| Amor Urbano, M; Aviñó Tarazona, V; Bayo Calero, J; Domínguez Senín, L; Rodriguez Garcés, MY; Santos-Rubio, MD | 1 |
| Bebyn, M; Koper, A; Koper, K; Śledzińska, P; Wileński, S | 1 |
| Arnold, D; Bassam, A; Chong, G; Cremolini, C; Csőszi, T; Cubillo Gracian, A; Dasari, A; Ducreux, M; Elez, E; Elme, A; Eng, C; Faugeras, L; García-Alfonso, P; Garcia-Carbonero, R; Ghiringhelli, F; Hochster, HS; Jones, J; Kania, M; Kasper, S; Kocsis, J; Krauss, J; Lonardi, S; Masuishi, T; Nanda, S; Paulson, AS; Randrian, V; Sartore-Bianchi, A; Satoh, T; Schelman, WR; Shergill, A; Sobrero, A; Tabernero, J; Tomasek, J; Van Cutsem, E; Yang, Z; Yao, J; Yoshino, T | 1 |
| Voutsadakis, IA | 1 |
| Altucci, L; Avallone, A; Cardone, C; Ciardiello, D; Ciardiello, F; De Falco, V; De Stefano, A; De Vita, F; Del Tufo, S; Della Corte, CM; Di Liello, A; Di Maio, M; Esposito, L; Famiglietti, V; Fazio, N; Marrone, F; Martinelli, E; Martini, G; Montesarchio, V; Napolitano, S; Troiani, T; Zampino, MG | 1 |
| Valeri, N; van de Haar, J; Voest, EE | 1 |
| Fakih, M; Prager, GW; Tabernero, J | 1 |
| Andreozzi, V; Barros, AG; Brito-da-Silva, J; Costa, AL; Costa, L; Cruz, J; Dâmaso, S; Félix, J; Mansinho, A; Marques, D; Mota, M; Pinheiro, S; Pratas, E; Quintela, A; Rodrigues, J; Teixeira, AR | 1 |
| Boku, N; Hara, H; Hirata, K; Hironaka, S; Kawakami, H; Masuishi, T; Matsumoto, T; Muro, K; Nagashima, K; Takahashi, N; Yamazaki, K | 1 |
| Kagawa, Y; Kunitomi, Y; Nakashima, M; Okude, R; Shinozaki, E; Tone, T | 1 |
| Doi, T; Ikeda, J; Ishikawa, T; Itoh, Y; Kirishima, T; Kudou, M; Kuriu, Y; Miyagawa, K; Nakanishi, M; Okayama, T; Otsuji, E; Takagi, T; Yoshida, N | 1 |
| Kawazoe, A; Kotani, D; Kuboki, Y; Mishima, S; Nakamura, H; Nakamura, Y; Okunaka, M; Shitara, K | 1 |
| Esaki, T; Fukuoka, S; Kajiwara, T; Kumekawa, Y; Makiyama, A; Masuishi, T; Moriwaki, T; Shimada, Y; Shiroyama, M; Takashima, A; Yamazaki, K | 1 |
| Fujii, H; Hirose, C; Hishida, S; Iihara, H; Kiyama, S; Kobayashi, R; Makiyama, A; Matsuhashi, N; Matsuoka, S; Ohata, K; Suzuki, A; Tajima, JY; Takahashi, T; Watanabe, D | 1 |
| Barghout, V; Duh, MS; Germain, G; Jacques, P; Laliberté, F; Patel, AK; Yenikomshian, MA | 1 |
| Alsina, M; Arkenau, HT; Beretta, GD; Catenacci, D; Doi, T; Fujitani, K; George, B; Ghidini, M; Ilson, DH; Makris, L; Mansoor, W; McGuigan, S; Prokharau, A; Shitara, K; Tabernero, J; Thuss-Patience, P; Van Cutsem, E; Zhavrid, E | 1 |
| Afzal, AR; Brezden-Masley, C; Cheung, WY; Dolley, A; Samawi, HH | 1 |
| Bekaii-Saab, T; Grothey, A; Marshall, JL | 1 |
| Chen, J; Lin, H; Peng, Y; Wang, J | 1 |
| Denda, T; Enomoto, M; Esaki, T; Fukuoka, S; Hatachi, Y; Ishikawa, T; Kajiwara, T; Kashiwada, T; Komatsu, Y; Kumekawa, Y; Makiyama, A; Masuishi, T; Moriwaki, T; Oki, E; Sakai, D; Shimada, Y; Sugimoto, N; Suto, T; Takashima, A; Tamura, T; Tsuchihashi, K; Tsuji, A; Ueno, H; Yamashita, K; Yamazaki, K | 1 |
| Li, J; Peng, Z; Shen, L; Wang, Q; Wang, X; Zhang, Q | 1 |
| Bando, H; Horasawa, S; Kaneko, A; Kawazoe, A; Kojima, T; Kotani, D; Kuboki, Y; Nakamura, Y; Shitara, K; Taniguchi, H; Tsuji, A; Yoshino, T | 1 |
| Grothey, A; Kasi, PM | 1 |
| Argilés, G; Baba, H; Benedetti, F; Cleary, JM; Esaki, T; Falcone, A; Garcia-Carbonero, R; Hamada, C; Hochster, HS; Komatsu, Y; Lenz, HJ; Makris, L; Mayer, RJ; Moriwaki, T; Muro, K; Nishina, T; Ohtsu, A; Peeters, M; Shimada, Y; Shinozaki, E; Sobrero, A; Sugimoto, N; Tanase, T; Tran, B; Tsuji, A; Tsuji, Y; Van Cutsem, E; Yamaguchi, K; Yamashita, F; Yamazaki, K; Yoshino, T; Zaniboni, A | 1 |
| Amellal, NC; André, T; Falcone, A; Fougeray, R; Gandossi, E; Kanehisa, A; Saunders, M | 1 |
| Krogh, M; Möller, S; Petersen, LN; Pfeiffer, P; Poulsen, LØ; Qvortrup, C; Thomsen, KG; Winther, SB; Yilmaz, M; Zitnjak, D | 1 |
| Carter, AM; Iveson, T; Mullamitha, S; Shiu, KK; Spooner, C; Stevens, D | 1 |
| Cao, M; Zhang, J; Zhou, M | 1 |
| Borner, M; De Dosso, S; Meisel, A; Siebenhüner, A; Wagner, AD | 1 |
| Fujii, H; Hirose, C; Iihara, H; Ishihara, T; Kitahora, M; Matsuhashi, N; Suzuki, A; Takahashi, T; Watanabe, D; Yamada, Y; Yoshida, K | 1 |
| Andrikou, K; Casadei-Gardini, A; Cascinu, S; Gelsomino, F; Orsi, G; Rovesti, G; Scartozzi, M; Spallanzani, A; Tamburini, E; Ulivi, P; Vagheggini, A | 1 |
| Colloca, G; Guarneri, D; Venturino, A | 1 |
| Ando, K; Fujimoto, Y; Kitao, H; Maehara, Y; Matsuoka, K; Mori, M; Nakanishi, R; Nukatsuka, M; Oki, E; Wakasa, T | 1 |
| Burge, M; Chantrill, L; Gibbs, P; Pavlakis, N; Price, T; Shapiro, J; Sjoquist, K | 1 |
| Lenz, HJ; Yoshino, T | 1 |
| Kadowaki, S; Kawakami, T; Kawamoto, Y; Komatsu, Y; Masuishi, T; Muranaka, T; Muro, K; Nakatsumi, H; Omae, K; Onozawa, Y; Tajika, M; Taniguchi, H; Yamazaki, K; Yasui, H; Yuki, S | 1 |
| Bonetti, A; Giuliani, J | 3 |
| Atlan, D; Bachet, JB; Becquart, M; Cicin, I; Cremolini, C; Falcone, A; Mounedji, N; Ozet, A; Phelip, JM; Portales, F; Price, T; Taieb, J; Van Cutsem, E; Vidot, L; Wyrwicz, L | 1 |
| Amellal, N; Argilés, G; Aubel, P; Borg, C; Danielewicz, I; Egorov, A; Falcone, A; Fedyanin, M; Garcia-Alfonso, P; Glynne-Jones, R; Kanehisa, A; Kroening, H; Moiseenko, V; Pfeiffer, P; Punt, CJA; Saunders, MP; Stroyakovskiy, D; Van Cutsem, E; Van de Wouw, AJ; Wasan, H | 1 |
| Hatachi, Y; Kato, T; Kotaka, M; Ogata, M; Ogata, T; Satake, H; Tsuji, A; Yasui, H | 1 |
| Cervantes, A; Huerta, M; Roda, D; Roselló, S | 1 |
| Fukuoka, T; Hirakawa, K; Iseki, Y; Kashiwagi, S; Maeda, K; Nagahara, H; Ohira, M; Okazaki, Y; Shibutani, M; Wang, EN | 1 |
| Kashiwa, M; Matsushita, R | 1 |
| Liu, H; Su, GL; Wang, JC; Wang, YY | 1 |
| Hasegawa, H; Kagawa, Y; Kato, T; Kii, T; Komatsu, Y; Kotaka, M; Makiyama, A; Matoba, K; Matsumoto, T; Mishima, H; Nagata, N; Nakamura, M; Oba, K; Oki, E; Okita, Y; Sakamoto, J; Satake, H; Takano, N; Terazawa, T; Tsuji, A; Watanabe, T; Yamazaki, K; Yasui, H; Yokota, M; Yoshino, T | 1 |
| Colaone, F; Hawkins, NS; Pollock, RF; Ross, PJ; Shergill, S; Walter, T | 1 |
| Hata, T; Kagawa, Y; Kato, T; Katsura, Y; Kawai, K; Masuzawa, T; Mori, R; Murakami, K; Murata, K; Naito, A; Nose, Y; Ohmura, Y; Sakamoto, T; Takeda, Y; Takeno, A | 1 |
| Argiles, G; Borg, C; Mayer, RJ; Moreno Vera, SR; Ohtsu, A; Sobrero, AF; Tabernero, J; Van Cutsem, E; Vidot, L | 1 |
| Antonuzzo, L; Castiglione, F; Di Costanzo, F; Lastraioli, E; Lavacchi, D; Messerini, L; Palmieri, VE | 1 |
| Brinker, A; Burdak-Rothkamm, S; Christiansen, S; Frenzel, T; Horn, M; Petersen, C; Rieckmann, T; Rothkamm, K; Schumacher, U; Stein, A | 1 |
| Kawakami, K; Nakashima, M; Takeuchi, M | 1 |
| Fukazawa, A; Hasegawa, S; Ishibashi, K; Ishida, H; Kamiyama, H; Koda, K; Kosugi, C; Kuramochi, H; Matsuda, A; Otsuka, T; Sakamoto, K; Sonoda, H; Yamada, T; Yamaguchi, S; Yoshida, H; Yoshida, Y; Yoshimatsu, K | 1 |
| Cheung, WY; Dolley, A; Kavan, P | 1 |
| Akagi, Y; Ando, K; Baba, H; Kabashima, A; Kashiwada, T; Kawanaka, H; Kotaka, M; Maehara, Y; Makiyama, A; Miwa, K; Miyamoto, Y; Mori, M; Noguchi, T; Oki, E; Saeki, H; Shimokawa, M; Yuge, K | 1 |
| Bonetti, A; Giuliani, J; Insolda, J; Pigozzi, E | 1 |
| Funato, Y; Koyama, T; Muro, K; Ozawa, D; Tajiri, M; Uetake, H; Yamaguchi, Y; Yoshino, T | 1 |
| Hamada, S; Ikeda, J; Komatsu, S; Konishi, T; Matsubara, D; Shibata, R; Shimomura, K; Shioaki, Y; Soga, K; Taniguchi, F | 1 |
| Akamatsu, H; Asaoka, T; Furukawa, K; Imasato, M; Inui, M; Iwamoto, K; Kishi, K; Mikamori, M; Moon, J; Naito, A; Nakahara, Y; Ohtsuka, M; Wada, R; Zenitani, S | 1 |
| Kawakami, K; Nakashima, M; Takeuchi, M; Tanaka, S | 1 |
| Azzurro, M; Bonetti, A; Fiorica, F; Giuliani, J; Ponturo, G; Ruzzenente, A | 1 |
| Bendell, JC; Falchook, GS; Hamada, K; Makris, L; Patel, MR | 1 |
| Amellal, N; Ciardiello, F; Fakih, M; Fougeray, R; Leger, C; Prager, GW; Tabernero, J; Taieb, J; van Cutsem, E | 1 |
| Arigami, T; Kita, Y; Kurahara, H; Maemura, K; Matsumoto, R; Mori, S; Natsugoe, S; Sasaki, K; Toda, H | 1 |
| Banzi, MC; Barone, CA; Bartolomeo, MD; Bergamo, F; Besse, MG; Blasi, L; Bordonaro, R; Costanzo, FD; Falcone, A; Frassineti, GL; Garufi, C; Giuliani, F; Latiano, TP; Martinelli, E; Personeni, N; Racca, P; Spione, M; Tamburini, E; Tonini, G; Zaniboni, A | 1 |
| Asayama, M; Kagawa, Y; Maehara, Y; Makiyama, A; Manaka, D; Matsuhashi, N; Mitsugi, K; Nakamura, M; Oba, K; Ojima, H; Oki, E; Okuda, H; Shimada, Y; Shiozawa, M; Takahashi, T; Watanabe, J; Yamazaki, K; Yoshida, K; Yoshino, T; Yuasa, Y | 1 |
| Ando, K; Fujimoto, Y; Kimura, Y; Kitao, H; Kotaka, M; Maehara, Y; Makiyama, A; Miyamoto, Y; Mori, M; Nakanishi, R; Oki, E; Qiu, S; Shimokawa, M | 1 |
| Amagasa, H; Ami, K; Ando, M; Fukuda, A; Gan, S; Ganno, H; Iida, S; Imai, K; Kajiyama, D; Kawaguchi, M; Maeda, F; Motoyama, K; Okano, Y; Tokitou, F; Yamada, A | 1 |
| Enomoto, M; Ishizaki, T; Kasahara, K; Katsumata, K; Kawakita, H; Matsudo, T; Mazaki, J; Nagakawa, Y; Shigoka, M; Tsuchida, A | 1 |
| Denda, T; Esaki, T; Fukuoka, S; Hatachi, Y; Kajiwara, T; Kumekawa, Y; Makiyama, A; Masuishi, T; Moriwaki, T; Niisato, Y; Shimada, Y; Sugimoto, N; Suto, T; Takashima, A; Yamazaki, K | 1 |
| Ciardiello, F; Grothey, A; Marshall, JL | 1 |
| Marshall, JL | 1 |
| Bekaii-Saab, TS; Loupakis, F; Marshall, JL | 1 |
| Bekaii-Saab, TS; Grothey, A; Prager, GW; Yoshino, T | 1 |
| Burge, M; Dean, A; Gibbs, P; Jalali, A; Lee, B; Lee, M; Lim, SH; Min, ST; Nott, L; Roohullah, A; Shapiro, J; Steel, S; Tognela, A; Wong, HL; Wong, R; Yip, D; Zimet, A | 1 |
| Aoki, H; Ito, Y; Kishida, N; Nishi, Y; Onishi, Y; Seo, Y; Sugiura, K; Takahashi, T; Tanaka, M; Tokura, H | 1 |
| Androulakis, N; Beletsi, A; Boukovinas, I; Chotzagiannoglou, V; Gourzoulidis, G; Karamouzis, M; Koulentaki, M; Koumarianou, A; Kourlaba, G; Papakotoulas, P; Samadas, E; Souglakos, J; Xynogalos, S | 1 |
| Denda, T; Gamoh, M; Goto, M; Iwata, M; Kagawa, Y; Kato, T; Komatsu, Y; Kotaka, M; Kuboki, Y; Makiyama, A; Oba, K; Oki, E; Satake, H; Shibuya, K; Soeda, J; Tanioka, H; Yamaguchi, K; Yamazaki, K; Yasui, H; Yoshino, T | 1 |
| Aleshin, A; Billings, PR; Ebi, H; Kato, T; Kotani, D; Mishima, S; Mori, M; Nakamura, Y; Oki, E; Rabinowitz, M; Sawada, K; Shirasu, H; Takemasa, I; Taniguchi, H; Yamanaka, T; Yoshino, T; Yukami, H | 1 |
| Ceribelli, A; Chilelli, MG; DE Marco, S; Gemma, D; Grande, R; Morandi, MG; Ruggeri, EM; Saltarelli, R; Signorelli, C; Sperduti, I; Spinelli, GP; Zoratto, F | 1 |
| Imai, H; Ishioka, C; Kato, S; Komine, K; Kuroki, M; Ohori, H; Otsuka, K; Ouchi, K; Sakamoto, Y; Shibata, H; Shimodaira, H; Shirota, H; Takahashi, M; Takahashi, S; Takahashi, Y; Tanaka, M; Tsuji, Y; Yamaguchi, H; Yamaguchi, T; Yoshioka, T | 1 |
| Court, OR; Shemilt, K | 1 |
| Fukazawa, A; Hasegawa, S; Ihara, K; Ishibashi, K; Ishida, H; Kamiyama, H; Koda, K; Kosugi, C; Kuramochi, H; Matsuda, A; Sakamoto, K; Sonoda, H; Yamada, T; Yoshida, H; Yoshida, Y; Yoshimatsu, K | 1 |
| Doi, T; Igarashi, A; Shitara, K; Takushima, Y; Yoshihara, H | 1 |
| Alsina, M; Arkenau, HT; Azcue, P; Catenacci, DVT; Doi, T; Fornaro, L; Fougeray, R; Ilson, DH; Lorenzen, S; Moreno, SR; Shitara, K; Tabernero, J; Van Cutsem, E; Zaanan, A | 1 |
| Essapen, S; Mendis, J; Tong, D; Wang, L | 1 |
| Cervantes, A; Ciardiello, D; Ciardiello, F; De Falco, V; Famiglietti, V; Fenocchio, E; Lombardi, P; Martinelli, E; Martini, G; Milanesio, M; Napolitano, S; Rosellò, S; Troiani, T; Vitale, P; Zanaletti, N | 1 |
| Carmona-Bayonas, A; Carriles Fernández, C; Cousillas Castiñeiras, A; Covela Rúa, M; De la Cámara Gómez, J; Fernández Montes, A; Garcia García, T; Gonzalez Villarroel, P; Jimenez-Fonseca, P; Martinez Lago, N; Méndez, JCM; Sanchez Cánovas, M; Vázquez Rivera, F | 1 |
| Abhyankar, R; Barghout, VE; Brais, LK; Duh, MS; Fuchs, CS; Huynh, L; Ng, K; Patel, AK; Yenikomshian, MA | 1 |
| Hochster, HS; Larson, H; Minnella, A; White, T | 1 |
| Barzi, A; Berger, MD; Cao, S; Gopez, R; Lenz, HJ; Loupakis, F; Marmorino, F; Mennitto, A; Miyamoto, Y; Murgioni, S; Ning, Y; Okazaki, S; Rossini, D; Schirripa, M; Suenaga, M; Yamaguchi, T; Yang, D; Zhang, W | 1 |
| Chen, Y; Fakih, M; Gong, J; Pillai, R; Shirasawa, S; Yang, L | 1 |
| Arnold, D; Hofheinz, RD; Kubicka, S; Vogel, A | 1 |
| Doi, T; Kajiwara, T; Kuboki, Y; Matsumoto, T; Mochizuki, N; Nishina, T; Nomura, S; Ohtsu, A; Okamoto, W; Sato, A; Shinozaki, E; Shitara, K; Tsushima, T; Yamazaki, K; Yoshino, T | 1 |
| Baba, E; Denda, T; Enomoto, M; Esaki, T; Fukuoka, S; Gosho, M; Ishikawa, T; Kajiwara, T; Kashiwada, T; Komatsu, Y; Kumekawa, Y; Makiyama, C; Moriwaki, T; Okuyama, H; Sakai, D; Satake, H; Shimada, Y; Sugimoto, N; Sugiyama, M; Suto, T; Takashima, A; Tamura, T; Taniguchi, H; Watanabe, T; Yamashita, K; Yamazaki, K | 1 |
| Barzi, A; Berger, MD; Borelli, B; Cao, S; Dadduzio, V; Gopez, R; Lenz, HJ; Loupakis, F; Miyamoto, Y; Ning, Y; Okazaki, S; Pietrantonio, F; Salvatore, L; Schirripa, M; Suenaga, M; Yamaguchi, T; Yang, D; Zhang, W | 1 |
| Kobunai, T; Matsuoka, K; Nukatsuka, M; Takechi, T | 1 |
| Bullement, A; Fougeray, R; Hatswell, AJ; Underhill, S | 1 |
| Abrahao, ABK; Berry, S; Chan, KKW; Ko, YJ | 1 |
| Bebeau, P; Bendell, JC; Buscaglia, M; Falcone, A; Kopetz, S; Mayer, RJ; Ohtsu, A; Van Cutsem, E; Yoshino, T | 1 |
| Armstrong, N; Duffy, S; Fayter, D; Joore, MA; Kleijnen, J; Lang, S; Pouwels, X; Ramaekers, BLT; van Giessen, A; Wolff, R; Worthy, G | 1 |
| Baars, A; Beerepoot, LV; Boot, H; Creemers, GJ; de Groot, JW; Hamberg, P; Jansen, RL; Kapiteijn, E; Koopman, M; Kwakman, JJM; Los, M; Opdam, FL; Punt, CJA; Schut, H; Sommeijer, DW; van Meerten, E; van Rooijen, JM; Vestjens, JH; Vink, G; Vulink, AJE | 1 |
| Iimori, M; Kiniwa, M; Kitao, H; Kurashige, J; Maehara, Y; Morodomi, Y; Nakanishi, R; Nakashima, Y; Oki, E; Saeki, H; Sugiyama, M | 1 |
| Ahn, JB; Bai, Y; Bi, F; Guo, W; Han, SW; Kim, TW; Li, J; Li, Q; Lin, D; Liu, T; Ma, D; Pan, H; Park, YS; Qin, S; Shen, L; Shi, C; Sriuranpong, V; Wu, C; Xu, J; Xu, R | 1 |
| Burki, TK | 1 |
| Benavides, M; Ciardiello, F; Denda, T; Grávalos, C; Laurent, S; Lenz, HJ; Loehrer, P; Longo-Munoz, F; Makris, L; Mayer, RJ; Muro, K; Ohtsu, A; Portales, F; Siena, S; Tsuji, Y; Van Cutsem, E; Winkler, R; Yamaguchi, K | 1 |
| Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T | 1 |
| Arnold, D; Moreno Vera, S; Mounedji, N; Prager, GW; Quintela, A; Stein, A; Taieb, J | 1 |
| Argilés, G; Élez, ME; Martini, G; Matos, I; Mulet, N; Noguerido, A; Tabernero, J | 1 |
| Ikeda, Y; Iwai, M; Kawachi, S; Kimura, M; Mitsuoka, M; Usami, E; Yasue, F; Yoshimura, T | 1 |
| Horiguchi, M; Sun, R; Wei, LJ | 1 |
| Akiba, T; Ishida, K; Kawahara, H; Matsumoto, N; Mouri, T; Yanaga, K | 1 |
| Antoniotti, C; Borelli, B; Ciardiello, F; Cremolini, C; Dal Maso, A; Di Bartolomeo, M; Falcone, A; Frassineti, GL; Lonardi, S; Martinelli, E; Masi, G; Miceli, R; Mosconi, S; Murgioni, S; Nichetti, F; Noventa, S; Pietrantonio, F; Rossini, D; Sforza, V; Tamburini, E; Troiani, T; Zucchelli, G | 1 |
| Garcia-Carbonero, R; Martinez-Perez, J; Riesco-Martinez, MC | 1 |
| Barghout, V; Duh, MS; Fuchs, CS; Patel, AK; Tabesh, M; Wynant, W; Xiao, Y; Yenikomshian, MA | 1 |
| Chu, E | 1 |
| Aisu, N; Daibo, K; Hasegawa, S; Kajitani, R; Kiyomi, F; Komono, A; Matsumoto, Y; Munechika, T; Sakamoto, R; Yoshida, Y | 1 |
| Bianconi, D; Drimmel, M; Gleiss, A; Kieler, M; Prager, GW; Scheithauer, W; Siebenhüner, A; Unseld, M; Winder, T | 1 |
| Baba, E; Denda, T; Esaki, T; Fukuoka, S; Ishikawa, T; Ito, M; Kajiwara, T; Kashiwada, T; Katsumata, K; Kishimoto, J; Komatsu, Y; Kumekawa, Y; Makiyama, A; Moriwaki, T; Oki, E; Okuyama, H; Sakai, D; Satake, H; Shimada, Y; Sugimoto, N; Suto, T; Takashima, A; Tamura, T; Taniguchi, H; Tsuchihashi, K; Ueno, H; Yamashita, K; Yamazaki, K | 1 |
| Baba, H; Denda, T; Esaki, T; Fujii, H; Goto, M; Hamamoto, Y; Komatsu, Y; Moriwaki, T; Muro, K; Nakayama, N; Nishina, T; Ohtsu, A; Shimada, Y; Shinozaki, E; Sugimoto, N; Takayama, T; Tanase, T; Tsuji, A; Tsuji, Y; Yamaguchi, K; Yamazaki, K; Yoshino, T | 1 |
| Barzi, A; Cho, SK; Hay, JW | 1 |
| Nakamura, A; Oki, M; Shinamura, N; Sugaya, M; Sugaya, T; Takagi, K | 1 |
| Matsuo, K; Matsuoka, K; Nakagawa, F; Okabe, H; Takechi, T; Tanaka, N | 1 |
| Cohen, SJ; Grothey, A; Hochster, HS; Makris, L; Mayer, RJ; Winkler, R | 1 |
| Fuchs, M; Karthaus, M; Kasper, S; Kisro, J; Müller, C; Rafiyan, MR; Schulz-Abelius, A; Stein, A | 1 |
| Gourzoulidis, G; Kourlaba, G; Maniadakis, N; Pentheroudakis, G; Petrakis, D; Souglakos, J | 1 |
| Akiyama, T; Baba, H; Baba, Y; Eto, K; Hiyoshi, Y; Iwagami, S; Kiyozumi, Y; Miyamoto, Y; Yohei, N; Yoshida, N | 1 |
| Kimura, M; Teramachi, H; Usami, E; Yoshimura, T | 1 |
| Fukuoka, T; Hirakawa, K; Iseki, Y; Maeda, K; Matsutani, S; Nagahara, H; Ohira, M; Shibutani, M; Wang, EN | 1 |
| Candamio Folgar, S; Carmona Campos, M; Cousillas Castiñeiras, A; Covela Rúa, M; de la Cámara Gómez, J; Fernandez Montes, A; Gallardo Martín, E; García Gómez, J; Gonzalez Villarroel, P; Jorge Fernández, M; Martinez Lago, N; Méndez Méndez, JC; París Bouzas, L; Pellón Augusto, ML; Reboredo López, M; Salgado Fernández, M; Vazquez Rivera, F | 1 |
| Ahn, DH; Bekaii-Saab, T; Benkhadra, R; Firwana, B; Hubbard, JM; Mody, K; Murad, MH; Sonbol, MB; Walden, DJ; Wang, Z | 1 |
| Kobunai, T; Matsuoka, K; Takechi, T | 1 |
| Chan, BM; Hochster, HS; Lenz, HJ | 1 |
| Kawano, Y; Matsuda, A; Matsumoto, S; Sakurazawa, N; Sekiguchi, K; Shinozuka, E; Suzuki, H; Yamada, T; Yoshida, H | 1 |
| Fukuoka, S; Kotani, D; Yoshino, T | 1 |
| Nakagawa, F; Nukatsuka, M; Saito, H; Sakata, M; Takechi, T; Uchida, J | 1 |
| Ishida, K; Matsuo, K; Nakagawa, F; Okabe, H; Sakamoto, K; Takechi, T; Tanaka, N; Tsukihara, H; Uchida, J | 1 |
| Chiba, M; Nakanishi, T; Takahashi, K; Tamai, I; Yoshisue, K | 1 |
| Ishida, K; Kazuno, H; Matsuo, K; Oguchi, K; Okabe, H; Osada, A; Sakamoto, K; Tanaka, N; Ueno, H; Yamada, Y; Yokogawa, T | 1 |
| Benedetti, F; Boucher, E; Cleary, JM; Falcone, A; Garcia-Carbonero, R; Hochster, H; Ito, M; Komatsu, Y; Lenz, HJ; Makris, L; Mayer, RJ; Mizuguchi, H; Mizunuma, N; Ohtsu, A; Peeters, M; Prenen, H; Shimada, Y; Sobrero, A; Tabernero, J; Tran, B; Van Cutsem, E; Yamazaki, K; Yoshino, T; Zaniboni, A | 1 |
| Mayor, S | 1 |
| Cleghorn, S | 1 |
| Boku, N; Doi, T; Fuse, N; Koizumi, W; Ohtsu, A; Shimada, K; Takinishi, Y; Yamazaki, K; Yoshino, T | 1 |
| Aimono, Y; Aoyama, Y; Kamoshida, T; Maruyama, T; Nemoto, M; Saito, Y; Sakamoto, R | 1 |
| Nakagawa, F; Nukatsuka, M; Takechi, T | 1 |
| Bendell, JC; Benedetti, F; Goldman, JW; Infante, JR; Lin, D; Mayer, RJ; Mizuguchi, H; Patel, MR; Rosen, LS; Zergebel, C | 1 |
| Fujimoto, T; Katsube, T; Matsumoto, A; Nakayama, M; Naritaka, Y; Okayama, S; Sakuma, A; Satake, M; Shimakawa, T; Shiozawa, S; Usui, T; Yamaguchi, K; Yano, Y; Yokomizo, H; Yoshimatsu, K | 1 |
| Antoniotti, C; Cremolini, C; Falcone, A; Loupakis, F; Marmorino, F; Masi, G; Moretto, R; Rossini, D; Salvatore, L; Schirripa, M | 1 |
| Argiles, G; Elez, ME; Grasselli, J; Sanz-Garcia, E; Tabernero, J | 1 |
| Hochster, HS; Uboha, N | 1 |
| Baba, H; Lenz, HJ; Miyamoto, Y | 1 |
| Bando, H; Doi, T; Fukuoka, S; Kawazoe, A; Kojima, T; Kotani, D; Kuboki, Y; Ohtsu, A; Okamoto, W; Shitara, K; Yoshino, T | 1 |
| Baba, H; Iimori, M; Kitao, H; Maehara, Y; Matsuoka, K; Miyamoto, Y; Oki, E; Saeki, H; Tokunaga, E | 1 |
| Goldberg, R | 1 |
| Akashi, K; Arita, S; Ariyama, H; Baba, E; Esaki, T; Hirano, G; Kusaba, H; Makiyama, A; Matsushita, Y; Mitsugi, K; Shibata, Y; Shimokawa, HK; Shirakawa, T; Tamura, S | 1 |
| Opdam, FL; van der Velden, DL; Voest, EE | 1 |
| Bando, H; Doi, T; Kuno, H; Muro, K; Nishina, T; Nomura, S; Ohtsu, A; Sato, A; Shitara, K; Takahashi, S; Yamaguchi, K; Yasui, H | 1 |
| Falcone, A; Salvatore, L | 1 |
| Braghiroli, MI; Fonseca, LG; Hoff, PM; Mota, JM | 1 |
| Fujita, N; Furuta, T; Hara, N; Katori, J; Muro, K; Uetake, H; Yoshino, T | 1 |
| Barni, S; Bertocchi, P; Petrelli, F; Zaniboni, A | 2 |
| Cecchini, M; Grothey, A; Hochster, HS; Kasi, PM; Kotani, D; Ohtsu, A; Ramanathan, RK; Shitara, K; Yoshino, T | 1 |
| Argiles, G; Carrato-Mena, A; Cervantes, A; Garcia-Carbonero, R; Gil-Calle, S; Gravalos, C; Limón, ML; Longo-Muñoz, F; Mizuguchi, H; Pericay, C; Tabernero, J | 1 |
| Doki, Y; Haraguchi, N; Hata, T; Hayashi, T; Kudo, T; Mizushima, T; Mori, M; Nishimura, J; Sakai, D; Satoh, T; Sueda, T; Sugiura, T; Takahashi, H | 1 |
| Marshall, JL; Salem, ME; Weinberg, BA | 1 |
| Aoyama, T; Hama, T; Inoue, A; Kawakami, K; Machida, Y; Suenaga, M; Sugisaki, T; Sugita, K; Suzuki, K; Takiguchi, T; Yamaguchi, K; Yamaguchi, T; Yokokawa, T | 1 |
| Ando, M; Fukutomi, A; Hamauchi, S; Ishihara, M; Kadowaki, S; Kito, Y; Komori, A; Machida, N; Masuishi, T; Mori, K; Muro, K; Narita, Y; Onozawa, Y; Tajika, M; Tanaka, T; Taniguchi, H; Todaka, A; Tsushima, T; Ura, T; Yamazaki, K; Yasui, H; Yokota, T | 2 |
| Burness, CB; Duggan, ST | 1 |
| Andrikou, K; Berardi, R; Bianconi, M; Bittoni, A; Cabras, F; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Maccaroni, E; Pusceddu, V; Restivo, A; Scartozzi, M; Scintu, F; Zorcolo, L | 1 |
| Matsuoka, K; Nakagawa, F; Suzuki, N; Takechi, T | 1 |
| Akagi, Y; Ishibashi, N; Kamei, H; Tanigawa, M; Uchida, M; Yamaguchi, K | 1 |
| Antonuzzo, L; Aprile, G; Baretti, M; Battaglin, F; Berenato, R; Beretta, G; Bozzarelli, S; Cinieri, S; Cremolini, C; de Braud, F; Falcone, A; Formica, V; Ghidini, M; Lonardi, S; Loupakis, F; Marmorino, F; Mennitto, A; Miceli, R; Morano, F; Mosconi, S; Petrelli, F; Pietrantonio, F; Rimassa, L; Rossini, D; Spada, D; Tamburini, E | 1 |
| Chu, E; Lee, JJ | 1 |
| Abbruzzese, JL; Fukushima, M; Hoff, P; Kopetz, S; Kuwata, K; Mita, A; Overman, MJ; Varadhachary, G; Wolff, RA; Xiong, H | 1 |
| Bijnsdorp, IV; Fukushima, M; Gokoel, S; Kruyt, FA; Peters, GJ; Smid, K | 1 |
| Sobrero, A | 1 |
| Baba, H; Esaki, T; Hamada, C; Komatsu, Y; Mizunuma, N; Moriwaki, T; Muro, K; Nishina, T; Ohtsu, A; Sugimoto, N; Tanase, T; Tsuji, A; Tsuji, Y; Yamaguchi, K; Yamazaki, K; Yoshino, T | 1 |
| Bijnsdorp, IV; Peters, GJ | 1 |
| Emura, T; Fukushima, M; Kitazato, K; Murakami, Y; Nakagawa, F | 1 |
| Emura, T; Fujioka, A; Fukushima, M; Ohshimo, H; Suzuki, N | 1 |
| Ackland, SP; Fukushima, M; Hoebe, EK; Peters, GJ; Temmink, OH; van der Born, K | 1 |
| Emura, T; Fukushima, M; Kazuno, H; Murakami, Y; Suzuki, N; Tsujimoto, H | 1 |
31 review(s) available for trifluridine and Colorectal Cancer
| Article | Year |
|---|---|
Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis.
Topics: Codon; Colonic Neoplasms; Colorectal Neoplasms; Frontotemporal Dementia; Humans; Mutation; Proto-Oncogene Proteins p21(ras); Pyrrolidines; Randomized Controlled Trials as Topic; Thymine; Trifluridine; Uracil | 2022 |
Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Frontotemporal Dementia; Humans; Rectal Neoplasms; Trifluridine; Uracil | 2023 |
A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Humans; Rectal Neoplasms; Trifluridine; Uracil | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Humans; Network Meta-Analysis; Phenylurea Compounds; Pyridines; Pyrrolidines; Quinazolines; Rectal Neoplasms; Thymine; Trifluridine; Uracil | 2019 |
Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
Topics: Antineoplastic Agents; Benzofurans; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Network Meta-Analysis; Phenylurea Compounds; Progression-Free Survival; Pyridines; Pyrrolidines; Quinazolines; Randomized Controlled Trials as Topic; Thymine; Time Factors; Trifluridine; Uracil | 2020 |
Comparison of efficacy and safety for patients with beyond second line treated metastatic colorectal cancer: a network meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents, Immunological; Cetuximab; Colorectal Neoplasms; Drug Combinations; Humans; Network Meta-Analysis; Panitumumab; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Pyridines; Pyrrolidines; Randomized Controlled Trials as Topic; Survival Analysis; Thymine; Trifluridine | 2020 |
Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Drug Combinations; Humans; Neoplasm Metastasis; Phenylurea Compounds; Pyridines; Pyrrolidines; Survival Rate; Switzerland; Thymine; Treatment Outcome; Trifluridine; Uracil | 2020 |
A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer.
Topics: Colorectal Neoplasms; Drug Combinations; Humans; Phenylurea Compounds; Pyridines; Pyrrolidines; Thymine; Trifluridine | 2020 |
Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Colorectal Neoplasms; Double-Blind Method; Drug Combinations; Humans; Microspheres; Neoplasm Metastasis; Network Meta-Analysis; Palliative Care; Phenylurea Compounds; Progression-Free Survival; Pyridines; Pyrrolidines; Randomized Controlled Trials as Topic; Thymine; Trifluridine; Uracil; Yttrium Radioisotopes | 2020 |
Dose-escalation strategy in refractory metastatic colorectal cancer: A change in terms of cost-effectiveness.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Combinations; Drug Costs; Humans; Phenylurea Compounds; Pyridines; Pyrrolidines; Thymine; Trifluridine | 2021 |
Metastatic Colorectal Cancer: Management With Trifluridine/Tipiracil
.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Humans; Male; Middle Aged; Nausea; Neoplasm Metastasis; Trifluridine; Vomiting | 2017 |
Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Phenylurea Compounds; Prognosis; Pyridines; Risk Assessment; Survival Analysis; Treatment Outcome; Trifluridine | 2017 |
A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Humans; Network Meta-Analysis; Phenylurea Compounds; Pyridines; Pyrrolidines; Thymine; Treatment Outcome; Trifluridine; Uracil | 2018 |
Trifluridine-Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Combinations; Humans; Pyrrolidines; Technology Assessment, Biomedical; Thymine; Trifluridine; Uracil | 2018 |
Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review.
Topics: Colorectal Neoplasms; Disease Progression; Drug Combinations; Drugs, Investigational; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Phenylurea Compounds; Pyridines; Pyrrolidines; Thymine; Trifluridine; Uracil | 2018 |
The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Pyrrolidines; Survival Rate; Thymine; Treatment Outcome; Trifluridine; Uracil | 2018 |
A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Humans; Neoplasm Metastasis; Phenylurea Compounds; Pyridines; Pyrrolidines; Randomized Controlled Trials as Topic; Survival Rate; Thymine; Treatment Outcome; Trifluridine; Uracil | 2019 |
The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Progression-Free Survival; Pyrrolidines; Thymidine Phosphorylase; Thymine; Trifluridine; Uracil | 2019 |
[Efficacy of TAS-102].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Thymine; Trifluridine; Uracil | 2015 |
TAS-102 for the treatment of metastatic colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Neoplasm Metastasis; Prognosis; Pyrrolidines; Survival Rate; Thymine; Trifluridine; Uracil | 2015 |
Current and advancing treatments for metastatic colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Combinations; ErbB Receptors; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Pyrrolidines; Ramucirumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Therapies, Investigational; Thymine; Trifluridine; Uracil; Vascular Endothelial Growth Factor A | 2016 |
TAS-102: a novel antimetabolite for the 21st century.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Clinical Trials as Topic; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Fluorouracil; Humans; Neoplasms; Pyrrolidines; Thymine; Treatment Outcome; Trifluridine; Uracil | 2016 |
A novel antimetabolite: TAS-102 for metastatic colorectal cancer.
Topics: Animals; Antineoplastic Agents; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Humans; Neoplasm Metastasis; Pyrrolidines; Randomized Controlled Trials as Topic; Survival Rate; Thymine; Trifluridine; Uracil | 2016 |
[Antitumor Molecular Mechanism of Trifluridine and Tipiracil Hydrochloride (TAS-102: TFTD)].
Topics: Animals; Cell Cycle; Colorectal Neoplasms; DNA; Drug Combinations; Drug Design; Drug Resistance, Neoplasm; Humans; Pyrrolidines; Thymine; Trifluridine; Uracil | 2016 |
TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Pyrrolidines; Thymidylate Synthase; Thymine; Trifluridine; Uracil | 2016 |
Review on TAS-102 development and its use for metastatic colorectal cancer.
Topics: Animals; Clinical Trials as Topic; Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Thymine; Trifluridine; Uracil | 2016 |
TAS-102 (Lonsurf) for the Treatment of Metastatic Colorectal Cancer. A Concise Review.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Randomized Controlled Trials as Topic; Thymine; Trifluridine; Uracil | 2016 |
Trifluridine/tipiracil and regorafenib: new weapons in the war against metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Neoplasm Metastasis; Phenylurea Compounds; Pyridines; Treatment Outcome; Trifluridine | 2016 |
Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Humans; Pyrrolidines; Thymine; Trifluridine | 2016 |
Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Humans; Medication Adherence; Neoplasm Metastasis; Pyrrolidines; Thymine; Trifluridine; Uracil | 2017 |
55 trial(s) available for trifluridine and Colorectal Cancer
| Article | Year |
|---|---|
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; Humans; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine | 2022 |
Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial.
Topics: Colorectal Neoplasms; Humans; Prospective Studies; Pyrrolidines; Quality of Life; Thymine; Trifluridine | 2022 |
A Phase I Clinical Trial of Trametinib in Combination with TAS-102 in Patients with Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild Type) Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Combinations; Humans; PTEN Phosphohydrolase; Pyridones; Pyrimidinones; Pyrrolidines; Thymine; Trifluridine | 2022 |
Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line tre
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Body Weight; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Multicenter Studies as Topic; Panitumumab; Prospective Studies; Pyrrolidines; Randomized Controlled Trials as Topic; Thymine; Trifluridine | 2022 |
Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Drug Combinations; Humans; Hyaluronic Acid; Sulfonamides; Trifluridine | 2023 |
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
Topics: Adult; Colonic Neoplasms; Colorectal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; Humans; Neutropenia; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil | 2022 |
Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Female; Humans; Male; Rectal Neoplasms; Trifluridine | 2023 |
Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Prospective Studies; Trifluridine; Uracil | 2022 |
Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Duration of Therapy; Humans; Trifluridine | 2023 |
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Frontotemporal Dementia; Humans; Irinotecan; Pyrrolidines; Rectal Neoplasms; Thymine; Trifluridine | 2023 |
Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Prognosis; Retrospective Studies; Stomach Neoplasms; Trifluridine; Uracil; Weight Loss | 2023 |
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Rectal Neoplasms; Trifluridine; Uracil | 2023 |
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Humans; Male; Panitumumab; Proto-Oncogene Proteins B-raf; Trifluridine | 2023 |
Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Esophagogastric Junction; Humans; Irinotecan; Paclitaxel; Pyrrolidines; Stomach Neoplasms; Trifluridine | 2023 |
Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Frontotemporal Dementia; Gemcitabine; Humans; Irinotecan; Prospective Studies; Trifluridine | 2023 |
Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Irinotecan; Rectal Neoplasms; Trifluridine; Uracil | 2023 |
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Double-Blind Method; Humans; Quality of Life; Rectal Neoplasms; Trifluridine; Vascular Endothelial Growth Factor A | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Humans; Panitumumab; Rectal Neoplasms; Trifluridine | 2023 |
Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G).
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Esophagogastric Junction; Frontotemporal Dementia; Humans; Prospective Studies; Ramucirumab; Stomach Neoplasms; Trifluridine; Young Adult | 2023 |
Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Gastrectomy; Humans; Male; Middle Aged; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine | 2020 |
Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine; Uracil; Young Adult | 2019 |
Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials.
Topics: Colorectal Neoplasms; Drug Combinations; Humans; Japan; Neutropenia; Pyrrolidines; Thymine; Trifluridine; Uracil | 2020 |
First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Protocols; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Pyrrolidines; Research Design; Thymine; Trifluridine; Uracil | 2020 |
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrrolidines; Salvage Therapy; Survival Rate; Thymine; Trifluridine; Uracil | 2020 |
Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Pyrrolidines; Quality of Life; Thymine; Trifluridine; Vascular Endothelial Growth Factor A | 2020 |
Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Fluorouracil; Humans; Pyrrolidines; Quality of Life; Thymine; Trifluridine | 2020 |
Comparative Cost-utility Analysis of Regorafenib and Trifluridine/Tipiracil in The Treatment of Metastatic Colorectal Cancer in Japan.
Topics: Adult; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Combinations; Humans; Japan; Phenylurea Compounds; Pyridines; Pyrrolidines; Quality-Adjusted Life Years; Thymine; Trifluridine | 2020 |
Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Thymine; Trifluridine | 2020 |
Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis.
Topics: Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Prognosis; Pyrrolidines; Quality of Life; Thymine; Trifluridine | 2020 |
Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Fluorouracil; Humans; Japan; Leucovorin; Pyrrolidines; Thymine; Trifluridine | 2021 |
Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Male; Prognosis; Pyrrolidines; Survival Rate; Thymine; Trifluridine | 2021 |
A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Male; Microsatellite Repeats; Middle Aged; Neoplasm Metastasis; Nivolumab; Pyrrolidines; Survival Rate; Thymine; Trifluridine | 2021 |
Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Pyrrolidines; Randomized Controlled Trials as Topic; Thymine; Trifluridine; Young Adult | 2021 |
Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer.
Topics: Aged; Colorectal Neoplasms; Drug Combinations; Female; Follow-Up Studies; Humans; International Agencies; Italy; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrrolidines; Quality of Life; Survival Rate; Thymine; Trifluridine | 2021 |
Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Humans; Mutation; Pyrrolidines; Thymine; Trifluridine | 2021 |
Monitoring FTD in the peripheral blood mononuclear cells of elderly patients with metastatic colorectal cancer administered FTD plus bevacizumab as first-line treatment.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Bevacizumab; Colorectal Neoplasms; DNA, Neoplasm; Drug Administration Schedule; Drug Combinations; Female; Humans; Leukocytes, Mononuclear; Male; Neoplasm Metastasis; Pyrrolidines; ROC Curve; Thymine; Trifluridine | 2021 |
Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy-Induced Febrile Neutropenia; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Pyrrolidines; Survival Analysis; Thymine; Treatment Outcome; Trifluridine | 2021 |
Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Humans; Panitumumab; Pyrrolidines; Thymine; Trifluridine | 2021 |
CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Circulating Tumor DNA; Colonic Neoplasms; Colorectal Neoplasms; Double-Blind Method; Humans; Japan; Neoplasm Recurrence, Local; Oxaliplatin; Prospective Studies; Pyrrolidines; Thymine; Trifluridine | 2021 |
Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Drug Combinations; Drug Monitoring; Female; Geriatric Assessment; Humans; Male; Neutropenia; Progression-Free Survival; Pyrrolidines; Survival Rate; Thymine; Trifluridine | 2021 |
TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Bevacizumab; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Drug Therapy, Combination; Female; Humans; Japan; Male; Middle Aged; Pyrrolidines; Thymine; Trifluridine; Uracil | 2017 |
Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Colorectal Neoplasms; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Mutation; Progression-Free Survival; Proto-Oncogene Proteins p21(ras); Pyrrolidines; Thymine; Time Factors; Trifluridine; Uracil; Young Adult | 2018 |
The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Pyrrolidines; Thymine; Treatment Outcome; Trifluridine; Uracil | 2018 |
Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cost-Benefit Analysis; Double-Blind Method; Drug Combinations; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Liver Neoplasms; Markov Chains; Palliative Care; Phenylurea Compounds; Prognosis; Pyridines; Pyrrolidines; Quality-Adjusted Life Years; Salvage Therapy; Survival Rate; Thymine; Trifluridine; United States; Uracil | 2018 |
Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Progression-Free Survival; Pyrrolidines; Research Design; Thymine; Trifluridine; Uracil; Withholding Treatment | 2018 |
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Pyrrolidines; Survival Analysis; Thymine; Trifluridine; Uracil | 2015 |
TAS-102 for metastatic refractory colorectal cancer.
Topics: Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pyrrolidines; Risk Assessment; Survival Analysis; Thymine; Treatment Outcome; Trifluridine; Uracil | 2015 |
Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Proto-Oncogene Proteins p21(ras); Pyrrolidines; Thymine; Trifluridine; Uracil | 2015 |
Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Fatigue; Febrile Neutropenia; Female; Gastrointestinal Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pyrrolidines; Salvage Therapy; Thymine; Treatment Outcome; Trifluridine; Uracil | 2015 |
A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil | 2016 |
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Colorectal Neoplasms; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Palliative Care; Prognosis; Pyrrolidines; Spain; Survival Rate; Thymine; Trifluridine; Uracil | 2017 |
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram.
Topics: Aged; Colon; Colorectal Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Drug Combinations; Female; Humans; Logistic Models; Male; Middle Aged; Neoplasm Metastasis; Nomograms; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyridines; Pyrrolidines; Thymine; Trifluridine; Uracil | 2017 |
Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrrolidines; Thymine; Trifluridine; Uracil | 2008 |
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrrolidines; ras Proteins; Thymine; Trifluridine; Uracil | 2012 |
147 other study(ies) available for trifluridine and Colorectal Cancer
| Article | Year |
|---|---|
Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Middle Aged; Neoplasm Recurrence, Local; Pyrrolidines; Rectal Neoplasms; Retrospective Studies; Thymine; Trifluridine; Uracil | 2022 |
Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Humans; Prognosis; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine; Uracil | 2021 |
The Efficacy and Safety of Trifluridine/Tipiracil Treatment for Elderly Patients With Metastatic Colorectal Cancer in a Real-world Setting.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Humans; Male; Progression-Free Survival; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine | 2021 |
Selective sensing of the nucleoside analogue, trifluridine and tipiracil in dosage form and biological matrices.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Nucleosides; Pyrrolidines; Thymine; Trifluridine; Uracil | 2022 |
Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Combinations; Humans; Pyrrolidines; Rectal Neoplasms; Thymine; Trifluridine; Uracil | 2022 |
The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis.
Topics: Aged; Colonic Neoplasms; Colorectal Neoplasms; Female; Humans; Liver Neoplasms; Male; Portugal; Prognosis; Pyrrolidines; Rectal Neoplasms; Retrospective Studies; Thymine; Trifluridine; Uracil | 2022 |
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer.
Topics: Angiopoietin-2; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Frontotemporal Dementia; Humans; Phenylurea Compounds; Pyridines; Rectal Neoplasms; Retrospective Studies; Trifluridine | 2022 |
Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Frontotemporal Dementia; Humans; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrrolidines; Rectal Neoplasms; Thymine; Trifluridine; Uracil | 2022 |
Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Frontotemporal Dementia; Humans; Prospective Studies; Pyrrolidines; Quality of Life; Rectal Neoplasms; Thymine; Trifluridine | 2022 |
Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasm Recurrence, Local; Phenylurea Compounds; Pyridines; Pyrrolidines; Thymine; Trifluridine; Uracil | 2022 |
Long-term survivors of metastatic colorectal cancer treated with trifluridine/tipiracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Survivors; Thymine; Trifluridine | 2022 |
Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model.
Topics: Colorectal Neoplasms; Frontotemporal Dementia; Humans; Leukocytes, Mononuclear; Pyrrolidines; Single-Cell Analysis; Thymine; Trifluridine | 2022 |
The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program Results of a Survey on Daily Practice Patterns for Patients with Metastatic Colorectal Cancer-A Swiss Perspective in the Context of an International Viewpoint.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Consensus; Early Detection of Cancer; Humans; Proto-Oncogene Proteins p21(ras); Rectal Neoplasms; Switzerland; Trifluridine | 2022 |
Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Middle Aged; Prognosis; Pyrrolidines; Rectal Neoplasms; Retrospective Studies; Thymine; Trifluridine; Uracil | 2022 |
Value-Based Analysis of Therapies in Refractory Metastatic Colorectal Cancer in US.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Cost-Benefit Analysis; Humans; Phenylurea Compounds; Pyridines; Quality-Adjusted Life Years; Rectal Neoplasms; Trifluridine | 2022 |
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Female; Humans; Male; Middle Aged; Retrospective Studies; Trifluridine; Uracil | 2022 |
Regorafenib and trifluridine/tipiracil in real clinical practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Male; Phenylurea Compounds; Retrospective Studies; Trifluridine; Uracil | 2022 |
An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Humans; Immune Checkpoint Inhibitors; Rectal Neoplasms; Trifluridine; Uracil | 2023 |
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Rectal Neoplasms; Trifluridine; Uracil | 2023 |
Evaluation of a Novel Combination Therapy, Based on Trifluridine/Tipiracil and Fruquintinib, against Colorectal Cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Frontotemporal Dementia; Humans; Mice; Trifluridine; Vascular Endothelial Growth Factor A | 2023 |
Trifluridine/Tipiracil in the Real-World Management of Metastatic Gastric and Gastroesophageal Junction Cancers in Canada.
Topics: Adult; Aged; Canada; Colorectal Neoplasms; Esophageal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; Humans; Stomach Neoplasms; Trifluridine; Uracil | 2022 |
Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Phenylurea Compounds; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine; Uracil | 2023 |
A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Phenylurea Compounds; Prospective Studies; Rectal Neoplasms; Trifluridine; United States; Uracil | 2023 |
Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Nausea; Rectal Neoplasms; Risk Factors; Trifluridine; Uracil; Vomiting | 2023 |
Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Frontotemporal Dementia; Humans; Irinotecan; Nivolumab; Stomach Neoplasms; Trifluridine; Uracil | 2023 |
Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Frontotemporal Dementia; Humans; Prospective Studies; Pyrrolidines; Quality of Life; Rectal Neoplasms; Trifluridine; Uracil | 2023 |
Analysis of neutropenia as a predictive factor of the efficacy of trifluridine-tipiracil treatment.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Middle Aged; Neutropenia; Prospective Studies; Pyrrolidines; Retrospective Studies; Trifluridine | 2023 |
Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Neoplasm Recurrence, Local; Prognosis; Pyrrolidines; Rectal Neoplasms; Retrospective Studies; Trifluridine; Uracil | 2023 |
Third-Line Therapy in Metastatic Colorectal Cancer.
Topics: Bevacizumab; Colorectal Neoplasms; Humans; Trifluridine | 2023 |
Third-Line Therapy in Metastatic Colorectal Cancer. Reply.
Topics: Bevacizumab; Colorectal Neoplasms; Humans; Trifluridine | 2023 |
The REWRITE Study - REal-WoRld effectIveness of TrifluridinE/tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Middle Aged; Rectal Neoplasms; Trifluridine; Uracil | 2023 |
Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan.
Topics: Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Frontotemporal Dementia; Humans; Japan; Retrospective Studies; Trifluridine; Uracil | 2023 |
Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Male; Middle Aged; Rectal Neoplasms; Retrospective Studies; Risk Factors; Trifluridine; Uracil | 2023 |
Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer-single institutional experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Ramucirumab; Retrospective Studies; Stomach Neoplasms; Trifluridine; Uracil | 2023 |
Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Frontotemporal Dementia; Humans; Neutropenia; Pyrrolidines; Rectal Neoplasms; Retrospective Studies; Risk Factors; Thymine; Trifluridine; Uracil | 2023 |
Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Humans; Neutropenia; Prognosis; Retrospective Studies; Trifluridine; Uracil | 2023 |
Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; Drug Combinations; Female; Humans; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Pyridines; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine | 2020 |
Real-world use of trifluridine/tipiracil for patients with metastatic colorectal cancer in Canada.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Canada; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Pyrrolidines; Thymine; Trifluridine; Uracil | 2019 |
Sequencing beyond the second-line setting in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Neoplasm Metastasis; Phenylurea Compounds; Prognosis; Pyridines; Pyrrolidines; Salvage Therapy; Survival Rate; Thymine; Trifluridine; Uracil | 2019 |
Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Phenylurea Compounds; Pyridines; Pyrrolidines; Retrospective Studies; Thymine; Treatment Outcome; Trifluridine; Uracil | 2020 |
Should we optimize cytotoxic therapy by dosing to neutropenia? Lessons from TAS-102.
Topics: Colorectal Neoplasms; Drug Combinations; Humans; Neutropenia; Pyrrolidines; Thymine; Trifluridine; Uracil | 2020 |
Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Combinations; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Pyrrolidines; Thymine; Treatment Outcome; Trifluridine; United Kingdom; Uracil | 2020 |
Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine; Uracil | 2020 |
Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Humans; Network Meta-Analysis; Panitumumab; Phenylurea Compounds; Progression-Free Survival; Prospective Studies; Pyridines; Pyrrolidines; Randomized Controlled Trials as Topic; Thymine; Trifluridine | 2020 |
Neutropenia in metastatic colorectal cancer receiving trifluridine/tipiracil.
Topics: Colorectal Neoplasms; Humans; Neutropenia; Pyrrolidines; Thymine; Trifluridine | 2020 |
Detection of trifluridine in tumors of patients with metastatic colorectal cancer treated with trifluridine/tipiracil.
Topics: Animals; Apoptosis; Cell Proliferation; Colorectal Neoplasms; Drug Combinations; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Prognosis; Pyrrolidines; Thymine; Trifluridine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Prognosis; Pyrrolidines; Quality of Life; Thymine; Trifluridine; Uracil | 2020 |
Reply to the letter to the editor 'Neutropenia in metastatic colorectal cancer receiving trifluridine/tipiracil' by Colloca et al.
Topics: Colorectal Neoplasms; Humans; Neutropenia; Pyrrolidines; Thymine; Trifluridine | 2020 |
Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Decision-Making; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Phenylurea Compounds; Progression-Free Survival; Pyridines; Pyrrolidines; Retrospective Studies; Thymine; Time Factors; Trifluridine; Tumor Burden; Uracil | 2019 |
Economic Sustainability of Trifluridine/Tipiracil for the Treatment of Refractory Metastatic Colorectal Cancer in Real Life.
Topics: Colorectal Neoplasms; Cost-Benefit Analysis; Drug Combinations; England; Humans; Pyrrolidines; Thymine; Trifluridine; Uracil; Wales | 2020 |
Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Japan; Male; Middle Aged; Phenylurea Compounds; Progression-Free Survival; Pyridines; Pyrrolidines; Retrospective Studies; Salvage Therapy; Thymine; Treatment Outcome; Trifluridine; Uracil | 2020 |
Trifluridine/tipiracil in earlier lines of chemotherapy for advanced colorectal cancer.
Topics: Bevacizumab; Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Thymine; Trifluridine | 2020 |
Combining Bevacizumab With Trifluridine/Thymidine Phosphorylase Inhibitor Improves the Survival Outcomes Regardless of the Usage History of Bevacizumab in Front-line Treatment of Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Pyrrolidines; Survival Analysis; Thymidine Phosphorylase; Thymine; Trifluridine; Uracil; Young Adult | 2020 |
Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Prognosis; Pyrrolidines; Retrospective Studies; Survival Rate; Thymine; Trifluridine | 2020 |
Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Disease Progression; DNA Mutational Analysis; Drug Combinations; Fluorouracil; Humans; Leucovorin; Liquid Biopsy; Male; Middle Aged; Mutation; Phenylurea Compounds; Pyridines; Pyrrolidines; ras Proteins; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Thymine; Trifluridine | 2020 |
Radiosensitisation and enhanced tumour growth delay of colorectal cancer cells by sustained treatment with trifluridine/tipiracil and X-rays.
Topics: Animals; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; Colorectal Neoplasms; Drug Combinations; Endoreduplication; Female; HCT116 Cells; Histones; HT29 Cells; Humans; Male; Mice; Polyploidy; Pyrrolidines; Radiation-Sensitizing Agents; Thymine; Trifluridine; Xenograft Model Antitumor Assays | 2020 |
Effectiveness and Safety of Regorafenib vs. Trifluridine/Tipiracil in Unresectable Colorectal Cancer: A Retrospective Cohort Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Female; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Phenylurea Compounds; Pyridines; Pyrrolidines; Retrospective Studies; Salvage Therapy; Survival Analysis; Thymine; Treatment Outcome; Trifluridine | 2020 |
Quality of life in a real-world study of patients with metastatic colorectal cancer treated with trifluridine/tipiracil.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Cross-Sectional Studies; Female; Humans; Male; Prospective Studies; Pyrrolidines; Quality of Life; Thymine; Trifluridine | 2020 |
Trifluridine/tipiracil or regorafenib in refractory metastatic colorectal cancer: from clinical trials to daily clinical practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Phenylurea Compounds; Pyridines; Pyrrolidines; Thymine; Trifluridine | 2020 |
Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Product Surveillance, Postmarketing; Pyrrolidines; Thymine; Trifluridine; Young Adult | 2021 |
[Long-Term Survivor with Recurrent Gastric Cancer Using Trifluridine/Tipiracil as a Late-Line Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Neoplasm Recurrence, Local; Pyrrolidines; Stomach Neoplasms; Survivors; Thymine; Trifluridine; Uracil | 2020 |
[Case Series of the TAS-102 plus Bevacizumab(Bev)Combination Therapy in Unresectable Advanced Colorectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Humans; Neoplasm Recurrence, Local; Pyrrolidines; Thymine; Treatment Outcome; Trifluridine | 2020 |
Salvage Therapy After Regorafenib or Trifluridine/Tipiracil Treatment of Metastatic Colorectal Cancer: A Conditional Landmark Analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Pyridines; Pyrrolidines; Retrospective Studies; Salvage Therapy; Survival Analysis; Thymine; Treatment Outcome; Trifluridine | 2021 |
[A Case of an Elderly Frail Patient with Unresectable Colorectal Cancer Controlled by Trifluridine/Tipiracil with Bevacizumab Therapy as a First-Line Treatment].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Female; Frail Elderly; Humans; Liver Neoplasms; Pyrrolidines; Thymine; Trifluridine | 2021 |
[Two Cases of Metastatic Colorectal Cancer Treated with TAS-102 plus Bevacizumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Humans; Neoplasm Recurrence, Local; Pyrrolidines; Thymine; Trifluridine; Uracil | 2021 |
Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment.
Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Comorbidity; Drug Combinations; Female; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Patient Selection; Phenylurea Compounds; Progression-Free Survival; Pyridines; Pyrrolidines; Retrospective Studies; Salvage Therapy; Survival Analysis; Thymine; Treatment Outcome; Trifluridine | 2021 |
How to incorporate a chemo-free interval into the management of metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; COVID-19; Disease Management; Drug Combinations; Humans; Neoplasm Metastasis; Phenylurea Compounds; Pyridines; Pyrrolidines; Quality of Life; Thymine; Time Factors; Trifluridine | 2020 |
Third-line treatments for the management of metastatic colorectal cancer: why to change the mechanism of action after frontline chemotherapy, and insights into management during the COVID-19 pandemic.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplasms; COVID-19; Disease Management; Drug Combinations; ErbB Receptors; Humans; Neoplasm Metastasis; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrrolidines; Thymine; Trifluridine | 2020 |
Transitioning from second-line to third-line therapy in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Decision-Making; Colorectal Neoplasms; Disease Management; Drug Combinations; Humans; Neoplasm Metastasis; Palliative Care; Phenylurea Compounds; Pyridines; Pyrrolidines; Thymine; Trifluridine | 2021 |
Optimizing the treatment sequence from second-line to third-line therapy in patients with metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Management; Disease Progression; Drug Combinations; Humans; Neoplasm Metastasis; Phenylurea Compounds; Progression-Free Survival; Pyridines; Pyrrolidines; Thymine; Trifluridine | 2020 |
Patient demographics and management landscape of metastatic colorectal cancer in the third-line setting: Real-world data in an australian population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Colonic Neoplasms; Colorectal Neoplasms; Demography; ErbB Receptors; Humans; Neoplasm Recurrence, Local; Proto-Oncogene Proteins p21(ras); Rectal Neoplasms; Retrospective Studies; Trifluridine | 2022 |
Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Combinations; Humans; Pyrrolidines; Quality-Adjusted Life Years; Thymine; Trifluridine | 2021 |
Cost-effectiveness of trifluridine/tipiracil as a third-line treatment of metastatic gastric cancer, including adenocarcinoma of the gastrohesophageal junction, among patients previously treated in Greece.
Topics: Adenocarcinoma; Colorectal Neoplasms; Cost-Benefit Analysis; Greece; Humans; Pyrrolidines; Quality-Adjusted Life Years; Stomach Neoplasms; Thymine; Trifluridine | 2022 |
Regorafenib-to-trifluridine/tipiracil Versus the Reverse Sequence for Refractory Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Real-life Experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Progression-Free Survival; Pyridines; Pyrrolidines; Thymine; Trifluridine | 2021 |
Lonsurf (trifluridine/tipiracil): Assessing the impact of dose related toxicities and progression free survival in (refractory) metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Progression-Free Survival; Rectal Neoplasms; Retrospective Studies; Trifluridine; Uracil | 2022 |
The Pre-treatment Lymphocyte-to-Monocyte Ratio Predicts Efficacy in Metastatic Colorectal Cancer Treated With TAS-102 and Bevacizumab.
Topics: Aged; Antineoplastic Agents, Immunological; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Female; Humans; Lymphocytes; Male; Middle Aged; Monocytes; Neoplasm Metastasis; Pyrrolidines; Thymine; Trifluridine | 2021 |
Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Combinations; Humans; Japan; Nivolumab; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil | 2021 |
Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study.
Topics: Colorectal Neoplasms; Humans; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil | 2021 |
Long Term Real-World Outcomes of Trifluridine/Tipiracil in Metastatic Colorectal Cancer-A Single UK Centre Experience.
Topics: Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine; United Kingdom | 2021 |
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data.
Topics: Colorectal Neoplasms; Drug Combinations; Humans; Phenylurea Compounds; Pyridines; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine; Uracil | 2021 |
Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asthenia; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neutropenia; Pyrrolidines; Thymine; Trifluridine; Young Adult | 2021 |
Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center.
Topics: Colorectal Neoplasms; Humans; Longitudinal Studies; Phenylurea Compounds; Pyridines; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine | 2021 |
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Disease-Free Survival; DNA Repair Enzymes; Drug Combinations; Drug Resistance, Neoplasm; Female; Genetic Association Studies; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Pyrrolidines; Retrospective Studies; Thymine; Treatment Outcome; Trifluridine; Uracil | 2017 |
MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Fluorouracil; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins p21(ras); Trifluridine | 2017 |
Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Prognosis; Propensity Score; Pyridines; Pyrrolidines; Retrospective Studies; Salvage Therapy; Survival Rate; Thymine; Trifluridine; Uracil | 2018 |
Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.
Topics: Antineoplastic Agents; California; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Equilibrative Nucleoside Transporter 1; Female; Gene Frequency; Genotype; Humans; Italy; Japan; Male; Neoplasm Metastasis; Organic Cation Transport Proteins; Organic Cation Transporter 2; Pharmacogenetics; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenotype; Polymorphism, Single Nucleotide; Predictive Value of Tests; Pyrrolidines; Retrospective Studies; Thymine; Treatment Outcome; Trifluridine; Uracil | 2017 |
Improved chemoradiation treatment using trifluridine in human colorectal cancer cells in vitro.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chemoradiotherapy; Colorectal Neoplasms; DNA Breaks, Double-Stranded; DNA Repair; Dose-Response Relationship, Radiation; HCT116 Cells; HT29 Cells; Humans; Ku Autoantigen; Rad51 Recombinase; Radiation Tolerance; Radiation-Sensitizing Agents; Trifluridine; Tumor Stem Cell Assay | 2017 |
Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Combinations; England; Female; Humans; Male; Middle Aged; Phenylurea Compounds; Pyridines; Pyrrolidines; Randomized Controlled Trials as Topic; Salvage Therapy; Thymine; Trifluridine; Uracil; Wales | 2018 |
Integrated safety summary for trifluridine/tipiracil (TAS-102).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Pyrrolidines; Randomized Controlled Trials as Topic; Thymine; Trifluridine; Uracil | 2018 |
Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Leukopenia; Male; Middle Aged; Netherlands; Neutropenia; Prognosis; Pyrrolidines; Thymine; Treatment Outcome; Trifluridine; Uracil | 2018 |
Monitoring trifluridine incorporation in the peripheral blood mononuclear cells of colorectal cancer patients under trifluridine/tipiracil medication.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Bone Marrow Cells; Colorectal Neoplasms; DNA; Drug Combinations; HCT116 Cells; Humans; Leukocytes, Mononuclear; Male; Mice, Inbred BALB C; Phytohemagglutinins; Pyrrolidines; Spleen; Thymine; Trifluridine; Uracil; Xenograft Model Antitumor Assays | 2017 |
TAS-102 in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Randomized Controlled Trials as Topic; Thymine; Treatment Outcome; Trifluridine; Uracil | 2018 |
Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Prognosis; Pyrrolidines; Risk Factors; Survival Analysis; Thymine; Trifluridine; Uracil | 2017 |
Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer.
Topics: Colorectal Neoplasms; Drug Combinations; Humans; Prognosis; Pyrrolidines; Thymine; Trifluridine; Uracil | 2018 |
Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Creatinine; Drug Combinations; Female; Humans; Leukocyte Count; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Neutrophils; Pyrrolidines; Retrospective Studies; Risk Factors; Thymine; Trifluridine; Uracil | 2018 |
Regorafenib or Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer? A Perspective on the Basis of Pharmacological Costs.
Topics: Colorectal Neoplasms; Humans; Phenylurea Compounds; Pyridines; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine | 2018 |
Interpreting the Benefit of Trifluridine/Tipiracil in Metastatic Colorectal Cancer With Respect to Progression-Free Survival and Overall Survival.
Topics: Colorectal Neoplasms; Double-Blind Method; Drug Combinations; Humans; Progression-Free Survival; Pyrrolidines; Respect; Thymine; Trifluridine; Uracil | 2018 |
Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Combinations; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Pyrrolidines; Retrospective Studies; Salvage Therapy; Survival Analysis; Thymine; Treatment Outcome; Trifluridine; Uracil | 2018 |
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Combinations; Female; Humans; Italy; Male; Middle Aged; Progression-Free Survival; Pyrrolidines; Registries; Thymine; Trifluridine; Uracil | 2018 |
Real-world Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Disease Progression; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Phenylurea Compounds; Pyridines; Pyrrolidines; Retrospective Studies; Thymine; Treatment Outcome; Trifluridine; United States; Uracil | 2018 |
How I treat chemorefractory metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lymphatic Metastasis; Neoplasm Staging; Nivolumab; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Pyridines; Pyrrolidines; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Thymine; Trastuzumab; Trifluridine; Uracil; Vascular Endothelial Growth Factor Receptor-1 | 2018 |
Biweekly Administration of TAS-102 for Neutropenia Prevention in Patients with Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Male; Middle Aged; Neutropenia; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine; Uracil | 2018 |
Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Phenylurea Compounds; Prognosis; Pyridines; Pyrrolidines; Retrospective Studies; Survival Rate; Thymine; Trifluridine; Uracil | 2018 |
Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C-Reactive Protein; Colorectal Neoplasms; Drug Combinations; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Nutritional Status; Phenylurea Compounds; Prognosis; Pyridines; Pyrrolidines; Retrospective Studies; Serum Albumin, Human; Survival Rate; Thymine; Trifluridine; Uracil | 2018 |
Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials.
Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Prognosis; Pyrrolidines; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Rate; Thymidine Kinase; Thymine; Trifluridine; Uracil | 2018 |
[Regorafenib and Trifluridine and Tipiracil Hydrochloride Can Potentially Improve the Survival Time for Patients with Advanced or Recurrent Colorectal Cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Humans; Male; Middle Aged; Phenylurea Compounds; Pyridines; Recurrence; Treatment Outcome; Trifluridine; Young Adult | 2018 |
Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Humans; Male; Mice, Nude; Phenylurea Compounds; Pyridines; Pyrrolidines; Thymine; Trifluridine | 2018 |
Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; Compassionate Use Trials; Drug-Related Side Effects and Adverse Reactions; Female; Germany; Humans; Male; Middle Aged; Prospective Studies; Pyrrolidines; Thymine; Trifluridine | 2018 |
Economic evaluation of trifluridine and tipiracil hydrochloride in the treatment of metastatic colorectal cancer in Greece.
Topics: Adult; Antimetabolites; Colorectal Neoplasms; Cost-Benefit Analysis; Greece; Humans; Pyrrolidines; Survival Analysis; Thymine; Trifluridine | 2019 |
Low Skeletal Muscle Mass before Salvage-Line Chemotherapy Is a Poor Prognostic Factor in Patients with Refractory Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Muscle, Skeletal; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyridines; Pyrrolidines; Retrospective Studies; Salvage Therapy; Thymine; Treatment Outcome; Trifluridine; Uracil | 2019 |
Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Pyrrolidines; Retrospective Studies; Tablets; Thymine; Treatment Outcome; Trifluridine; Uracil | 2019 |
Prognostic Significance of the C-Reactive Protein-to-Albumin Ratio in Patients With Metastatic Colorectal Cancer Treated With Trifluridine/Thymidine Phosphorylase Inhibitor as Later-line Chemotherapy.
Topics: Aged; Albumins; Antineoplastic Agents; C-Reactive Protein; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Inflammation; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Thymidine Phosphorylase; Treatment Outcome; Trifluridine | 2019 |
Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Nomograms; Prognosis; Progression-Free Survival; Pyrrolidines; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Spain; Survival Rate; Thymine; Trifluridine; Uracil | 2020 |
ChIP-seq Analysis to Explore DNA Replication Profile in Trifluridine-treated Human Colorectal Cancer Cells
Topics: Antimetabolites, Antineoplastic; Bromodeoxyuridine; Colorectal Neoplasms; DNA Replication; HCT116 Cells; Humans; Sequence Analysis, DNA; Trifluridine | 2019 |
The Onset of Grade ≥3 Neutropenia Is Associated With Longer Overall Survival in Metastatic Colorectal Cancer Patients Treated With Trifluridine/Tipiracil.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Neutropenia; Pyrrolidines; Survival Analysis; Thymine; Trifluridine; Uracil | 2019 |
Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts Survival After TAS-102 Treatment of Patients With Metastatic Colorectal Cancer.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Colorectal Neoplasms; Drug Combinations; Female; Humans; Leukocyte Count; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Platelet Count; Prognosis; Progression-Free Survival; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine; Uracil | 2019 |
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Humans; Irinotecan; Male; Mice; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil; Xenograft Model Antitumor Assays | 2015 |
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Cetuximab; Chromatography, Liquid; Colorectal Neoplasms; Disease Models, Animal; Drug Combinations; Humans; Male; Mice; Mice, Nude; Panitumumab; Pyrrolidines; Tandem Mass Spectrometry; Thymine; Trifluridine; Uracil; Xenograft Model Antitumor Assays | 2015 |
Involvement of Concentrative Nucleoside Transporter 1 in Intestinal Absorption of Trifluridine Using Human Small Intestinal Epithelial Cells.
Topics: Animals; Caco-2 Cells; Carrier Proteins; Cell Line, Tumor; Cell Membrane Permeability; Colorectal Neoplasms; Drug Combinations; Epithelial Cells; Humans; Intestinal Absorption; Intestine, Small; Membrane Transport Proteins; Nucleoside Transport Proteins; Nucleosides; Oocytes; Pyrrolidines; Thymine; Trifluridine; Uracil; Xenopus | 2015 |
Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; DNA, Neoplasm; Drug Combinations; Equilibrative Nucleoside Transporter 1; Equilibrative-Nucleoside Transporter 2; Fluorouracil; HCT116 Cells; Humans; Male; Pyrophosphatases; Pyrrolidines; Substrate Specificity; Thymidine Kinase; Thymine; Trifluridine; Uracil | 2015 |
TAS-102 prolongs overall survival in refractory colorectal cancer, study shows.
Topics: Adenocarcinoma; Colorectal Neoplasms; Female; Humans; Male; Trifluridine; Uracil | 2015 |
Drug Improves Survival in Refractory Colorectal Cancer.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Humans; Pyrrolidines; Survival Analysis; Thymine; Treatment Outcome; Trifluridine; Uracil | 2015 |
[Initial Evaluation of the Efficacy and Safety of Tablets Containing Trifluridine and Tipiracil Hydrochloride--Safety Measures Devised by a Multidisciplinary Team Including a Pharmaceutical Outpatient Clinic].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Humans; Male; Middle Aged; Patient Care Team; Recurrence; Tablets; Treatment Outcome; Trifluridine | 2015 |
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Death; Cell Proliferation; Colorectal Neoplasms; Drug Combinations; HCT116 Cells; Humans; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Pyrrolidines; Stomach Neoplasms; Thymine; Treatment Outcome; Trifluridine; Tumor Burden; Uracil; Xenograft Model Antitumor Assays | 2015 |
[Short-Term Outcome of TAS-102 for Refractory Metastatic Colorectal Cancer].
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Pyrrolidines; Retrospective Studies; Salvage Therapy; Thymine; Treatment Outcome; Trifluridine; Uracil | 2015 |
Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Salvage Therapy; Thymine; Treatment Outcome; Trifluridine; Uracil | 2016 |
Emerging phase 3 data in relapsed/refractory metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Phenylurea Compounds; Pyridines; Pyrrolidines; Retreatment; Thymine; Treatment Outcome; Trifluridine; Uracil | 2016 |
Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrrolidines; Salvage Therapy; Survival Analysis; Thymine; Treatment Outcome; Trifluridine; Uracil | 2016 |
In brief: trifluridine/tipiracil (Lonsurf) for metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Enzyme Inhibitors; Humans; Neoplasm Metastasis; Pyrrolidines; Thymidine Phosphorylase; Thymine; Treatment Outcome; Trifluridine; Uracil | 2016 |
An interview with Alfredo Falcone and Lisa Salvatore: RECOURSE and trifluridine/tipiracil in metastatic colorectal cancer.
Topics: Achievement; Antineoplastic Combined Chemotherapy Protocols; Career Choice; Clinical Trials as Topic; Colorectal Neoplasms; Disease Management; Drug Discovery; Humans; Neoplasm Metastasis; Neoplasm Staging; Pyrrolidines; Research; Thymine; Treatment Outcome; Trifluridine | 2016 |
TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Product Surveillance, Postmarketing; Pyrrolidines; Thymine; Trifluridine; Uracil | 2016 |
TAS-102, the first "cardio-gentle" fluoropyrimidine in the colorectal cancer landscape?
Topics: Cardiotoxicity; Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Thymine; Treatment Outcome; Trifluridine; Uracil | 2016 |
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
Topics: Age Factors; Aged; Antineoplastic Agents; Chemotherapy-Induced Febrile Neutropenia; Clinical Trials, Phase III as Topic; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Pyrrolidines; Thymine; Trifluridine; United States; Uracil | 2016 |
Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Pyridines; Pyrrolidines; Randomized Controlled Trials as Topic; Thymine; Treatment Outcome; Trifluridine; Uracil | 2016 |
Self-Reported Adherence to Trifluridine and Tipiracil Hydrochloride for Metastatic Colorectal Cancer: A Retrospective Cohort Study.
Topics: Abdominal Pain; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Appetite; Colorectal Neoplasms; Female; Humans; Male; Medication Adherence; Middle Aged; Nausea; Neutropenia; Pyrrolidines; Retrospective Studies; Self Report; Thymine; Trifluridine; Vomiting | 2016 |
Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Neutropenia; Prognosis; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine; Uracil | 2017 |
The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Capecitabine; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Phenylurea Compounds; Pyridines; Pyrrolidines; Thymine; Trifluridine; Uracil | 2017 |
Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison.
Topics: Aged; Antineoplastic Agents; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Pyridines; Pyrrolidines; Retrospective Studies; Survival Rate; Thymine; Treatment Outcome; Trifluridine; Uracil | 2017 |
Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; HCT116 Cells; HT29 Cells; Humans; Indoles; Inhibitory Concentration 50; Male; Mice, Inbred BALB C; Mice, Nude; Pyrrolidines; Thymine; Trifluridine; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Interstitial pneumonia in a patient treated with TAS-102 for metastatic colorectal cancer: a case report.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Humans; Japan; Lung Diseases, Interstitial; Male; Middle Aged; Pyrrolidines; Thymine; Trifluridine; Uracil | 2016 |
Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines.
Topics: Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase; Genes, ras; Humans; Proto-Oncogene Proteins c-akt; Quinazolines; Thymidylate Synthase; Trifluridine | 2010 |
TAS-102 in refractory colorectal cancer: caution is needed.
Topics: Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Pyrrolidines; Thymine; Trifluridine; Uracil | 2012 |
TAS-102: more than an antimetabolite.
Topics: Colorectal Neoplasms; Female; Humans; Male; Trifluridine; Uracil | 2012 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Coloring Agents; Drug Combinations; Drug Resistance, Neoplasm; Fluorouracil; Globins; Humans; Liver; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Chemical; Neoplasm Metastasis; Neoplasm Transplantation; Polymerase Chain Reaction; Pyrrolidines; Sensitivity and Specificity; Tetrazolium Salts; Thiazoles; Thymidine Phosphorylase; Thymine; Trifluridine; Uracil | 2004 |
Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Line, Tumor; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Humans; Macaca fascicularis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Thymidine; Thymidine Phosphorylase; Time Factors; Trifluridine; Xenograft Model Antitumor Assays | 2005 |
Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; DNA Repair; Humans; Organoplatinum Compounds; Oxaliplatin; Trifluridine | 2007 |
Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Division; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Floxuridine; Fluorouracil; Humans; Neoplasm Proteins; Thymidylate Synthase; Trifluridine; Tumor Cells, Cultured | 2000 |